NDC 0310-3040

SAPHNELO

Anifrolumab

SAPHNELO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Anifrolumab.

Product ID0310-3040_1585fae3-a657-45e9-907a-e43e69798ef4
NDC0310-3040
Product TypeHuman Prescription Drug
Proprietary NameSAPHNELO
Generic NameAnifrolumab
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-07-30
Marketing CategoryBLA /
Application NumberBLA761123
Labeler NameAstraZeneca Pharmaceuticals LP
Substance NameANIFROLUMAB
Active Ingredient Strength300 mg/2mL
Pharm ClassesType I Interferon Receptor Antagonist [EPC], Type I Interferon Receptor Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0310-3040-00

1 VIAL, GLASS in 1 CARTON (0310-3040-00) > 2 mL in 1 VIAL, GLASS
Marketing Start Date2021-07-30
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [SAPHNELO]

Mark Image

Registration | Serial
Company
Trademark
Application Date
SAPHNELO
SAPHNELO
88833575 not registered Live/Pending
AstraZeneca AB
2020-03-13

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.